Total Hip Arthroplasty: Multiple Blocks by UltraSound

NCT ID: NCT01276925

Last Updated: 2015-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients undergoing total hip arthroplasty may experience severe postoperative pain. This is normally treated with opioids, which can cause side effects such as nausea, vomiting, obstipation and sedation. The hypothesis is that patients receiving peripheral nerve blockade of three nerves leading pain stimuli from the hip will experience less pain, will consume less opioid and therefore have less side effects, and will be mobilized more quickly than patients not receiving the peripheral nerve blockade.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Total hip arthroplasty (THA) may cause significant postoperative pain. The patients are often elderly, and frequently have other diseases or ailments. Postoperative pain treatment must focus on effective pain relief, keeping adverse effects to a minimum, enhancing physical rehabilitation and reducing postoperative morbidity.

Postoperative pain after hip surgery can be treated in different ways; i.e. paracetamol, NSAIDs, opioids, peripheral nerve blocks and epidural catheter. The choice seems to be influenced by local experience, education and personal preferences. Frequently, a multimodal approach is used with a combination of weak analgetics, opioids and maybe regional anaesthetic techniques.

The sensory innervation of the hip is through branches from the lumbar and sacral plexuses. The femoral nerve (FN), the obturator nerve (anterior branch) (ONA) and the lateral femoral cutaneous nerve (LCFN) all stem from the lumbar plexus. The FN and ONA directly supply the hip joint. LCFN innervates the skin on the lateral part of the thigh, where the incision for THA is often made.

The psoas compartment block provides good pain relief after THA, but the block can be associated with more frequent complications than other regional blockades for the lower extremity. Furthermore, the technique is difficult, and requires sub-specialized anaesthetists. In addition, it is often necessary to use electrical nerve stimulation together with ultrasound guidance to achieve a sufficient block.

Blockade of the FN is standard for hip fractures in our hospital, but not standard for THA. Because of the analgetic effect in hip fractures, the PROSPECT group recommends blockade of FN for THA as well, though specific evidence is scarce on the subject.

Blockade of the obturator nerve has been shown to provide pain relief for the hip joint, although the findings are not consistent, probably because of the varying innervation of the hip. The nerve is difficult to locate blindly, and location by nerve stimulator can be uncomfortable for the patient. Furthermore, the anatomic variations of the nerve and its branches is quite substantial.

Previously, nerves were located by surface anatomic landmarks or by nerve stimulation. In the past 6-7 years, the use of ultrasound guidance has become an increasingly effective aid for applying peripheral nerve blockades with continuingly improving technology.

Ultrasound-guided blockade of the three nerves (FN, ONA and LFCN) for postoperative pain treatment for THA is to our knowledge not previously described in the literature. From our knowledge of the anatomic course of the nerves, the investigators assume that the blockades can provide effective pain relief in this clinical context.

Our aim in this trial is to study the effect of ultrasound-guided periferal nerve blockade of the femoral nerve, the obturator nerve (anterior branch), and the lateral femoral cutaneous nerve on postoperative pain, opioid consumption and mobilization after THA.

The investigators want to describe the effect of blockade of the three nerves on pain, compared to placebo (injections with a well-known local analgesic drug compared to injections with isotonic saline).

Because it is desirable to have the patient mobilized as quickly as possible after operation, it seems optimal to cause as little motor blockade as possible. The investigators therefore also want to investigate whether pain relief with blockade of ONA and LCFN without blockade of FN is better than or equal to placebo.

The investigators want to study the possible differences in adverse effects, including motor blockade, between the groups with active nerve blockades, with and without blockade of FN.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B3: Blockade of three nerves

Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

Ultrasound

Intervention Type DEVICE

All nerve blockades will be performed with ultrasound guidance.

Peripheral nerve blockade

Intervention Type PROCEDURE

All patients will receive injections around the three nerves before surgery.

Total hip arthroplasty

Intervention Type PROCEDURE

All patients undergoes total hip arthroplasty.

Bupivacaine

Intervention Type DRUG

5 mg/ml. 3 ml for spinal anaesthesia.

B2: Blockade of 2 nerves

Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.

Sham blockade of the femoral nerve with saline.

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

Ultrasound

Intervention Type DEVICE

All nerve blockades will be performed with ultrasound guidance.

Peripheral nerve blockade

Intervention Type PROCEDURE

All patients will receive injections around the three nerves before surgery.

Saline

Intervention Type DRUG

Isotonic. 10 ml for the femoral nerve.

Total hip arthroplasty

Intervention Type PROCEDURE

All patients undergoes total hip arthroplasty.

Bupivacaine

Intervention Type DRUG

5 mg/ml. 3 ml for spinal anaesthesia.

K: Control group

Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.

Group Type SHAM_COMPARATOR

Ultrasound

Intervention Type DEVICE

All nerve blockades will be performed with ultrasound guidance.

Peripheral nerve blockade

Intervention Type PROCEDURE

All patients will receive injections around the three nerves before surgery.

Saline

Intervention Type DRUG

Isotonic. 10 ml for the femoral nerve.

Total hip arthroplasty

Intervention Type PROCEDURE

All patients undergoes total hip arthroplasty.

Bupivacaine

Intervention Type DRUG

5 mg/ml. 3 ml for spinal anaesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine

7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

Intervention Type DRUG

Ropivacaine

7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

Intervention Type DRUG

Ultrasound

All nerve blockades will be performed with ultrasound guidance.

Intervention Type DEVICE

Peripheral nerve blockade

All patients will receive injections around the three nerves before surgery.

Intervention Type PROCEDURE

Saline

Isotonic. 10 ml for the femoral nerve.

Intervention Type DRUG

Total hip arthroplasty

All patients undergoes total hip arthroplasty.

Intervention Type PROCEDURE

Bupivacaine

5 mg/ml. 3 ml for spinal anaesthesia.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Naropin Naropin Marcain spinal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Minimum 18 years of age
* Patients scheduled for primary, unilateral hip arthroplasty with spinal anaesthesia
* Patients who have given their written and informed consent to participation after having understood the content and limitations of the protocol fully
* ASA 1-3

Exclusion Criteria

* Patients who are not able to co-operate
* Patients who do not speak or understand Danish
* Daily use of opioids corresponding to 40 mg of morphine daily
* Allergy towards the drugs used in the study
* Drug abuse (investigators judgement)
* Alcohol consumption larger than advised by the Danish National Board of Health
* Spinal anaesthesia is contraindicated or the patient wants a general anaesthesia
* Patients in whom the blockade procedure or the spinal anaesthesia procedure cannot be completed because of technical difficulties
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bispebjerg Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kenneth Jensen

MD, BBA

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Birgitte M Krogh, MD

Role: PRINCIPAL_INVESTIGATOR

Bispebjerg Hospital

Kenneth Jensen, MD

Role: STUDY_DIRECTOR

Bispebjerg Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bispebjerg Hospital

Copenhagen, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Birgitte M Krogh, MD

Role: CONTACT

+45 50507405

Kenneth Jensen, MD

Role: CONTACT

+45 40259668

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kenneth Jensen, MD

Role: primary

+45 40259668

B

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BBH-Z-THAMBUS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.